HQY vs NVS
HealthEquity vs Novartis AG — AI-powered side-by-side comparison
| Metric | HQY | NVS |
|---|
| AI Score |
64
|
64
|
| Price |
$106.83
|
$156.79
|
| P/E Ratio |
38.75×
|
23.75×
|
| ROE |
10.2%
|
30.5%
|
| Revenue Growth YoY |
—
|
—
|
| Gross Margin |
72.7%
|
74.3%
|
| Debt / Equity |
0.48×
|
1.18×
|
| Dividend Yield |
0.0%
|
2.9%
|
| RSI (14) |
65.8
|
55.8
|
| Beta |
0.21
|
0.462
|
| Expected Upside |
+1.0%
|
+2.7%
|
AI Committee View
Current Innellis committee reasoning for HQY versus NVS.
The committee scores are tied.
HQY and NVS both score 64/100.
HQY Committee View
80% agreement
5 analysts
The committee is genuinely divided. Growth Analyst sees a compelling case — 4 consecutive earnings beats -- consistent execution. Risk Analyst remains cautious — bollinger bandwidth of 15.3% signals elevated volatility. This disagreement is itself the signal — the setup is not clean in either direction.
Bull Case
- 4 consecutive earnings beats -- consistent execution — Growth
- Quarter-over-quarter growth rate is ACCELERATING, not just positive — Growth
- Price structure making higher highs and higher lows — Technical
Bear Case
- Weekly RSI at 76 -- overbought on the larger timeframe too — Technical
- Bollinger bandwidth of 15.3% signals elevated volatility — Risk
NVS Committee View
67% agreement
6 analysts
The primary driver is news sentiment is positive (+0.67 across 9 articles, 14d). The main limiting factor is price-to-book of 5.6x prices in significant intangible value. The committee is constructive but not yet at full conviction.
Bull Case
- ROE of 29.9% shows genuine earnings power backing the valuation — Value
- Dividend yield of 2.9% pays you to wait — Value
- Quarter-over-quarter growth rate is ACCELERATING, not just positive — Growth
Bear Case
- Price-to-book of 5.6x prices in significant intangible value — Value
- EPS declining -3.5% YoY despite any revenue growth — Growth
- MACD histogram negative -- bearish momentum — Technical